Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: December 16, 2019

DrugPatentWatch Database Preview

Litigation Details for Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2015)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2015)

Docket   Start Trial Date Filed 2015-09-08
Court District Court, D. Delaware Date Terminated
Cause 35:145 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Patents 4,005,063; 4,335,121; 4,992,474; 5,164,194; 5,889,015; 5,972,920; 6,759,398; 7,629,335; 8,071,073; 8,163,723; 8,168,620; 9,259,428
Attorneys Andrew Colin Mayo; John G. Day; John W. Shaw; Karen Elizabeth Keller; Steven J. Balick
Link to Docket External link to docket
Small Molecule Drugs cited in Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.

Details for Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2016-11-11 101 Exhibit A 4:59-5:4; 5:63-6:7; 6:59-7:3; 7:30-61. ’428 Patent (MEDA_TEVA… The ’620, 723, and ’428 patents arise from the same patent family and share substantially similar… ’723, and ’428 patents contain many of the same references. For citations to patents, the parties incorporate… MEDA_TEVA_00000733 (Non-Patent U.S. Patent No. 5,889,015 (see, e.g., Col. … MEDA_TEVA_00001353 (Non-Patent U.S. Patent No. 8,071,073 (see, e.g., Col. External link to document
2016-11-14 104 Correction ("CoC") for U.S. Patent No. 9,259,428 ('" 428 patent") into this case. (D.I…inadvertent typographical errors" in the '428 patent. (D.I. 62 at 1) "On May 3, 2016, the PTO issued…requested Certificate of Correction for the '428 patent." (Id.) Plaintiffs explain that thereafter…indefiniteness arguments regarding claim 28 of '_428 patent, arguments that would be affected by introduction…litigating the uncorrected version of the '428 patent. (See D.I. 65 at 5) (discussing litigation that External link to document
2016-12-07 113 of U.S. Patent Nos. 8,163,723; 8,168,620; and 9,259,428. With respect to the '428 patent, the PTO…construe claims 28-30 of the '428 patent, which, in the uncorrected patent, contain a typographical error…addressing construction of claims 28-30 of the '428 patent, within one week of the date of this order. Signed…additional exhibits are documents from the '428 patent's prosecution history, including a listing …in the,context of claims 28-30 of the '428 patent. 3. D~fendant opposes Plaintiffs External link to document
2016-03-18 28 Initial Infringement Contentions for U.S. Patent Nos. 8,163,723, 8,168,620, and 9,259,428 filed by Cipla…8 September 2015 1:15-cv-00785 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.